



**Proteome Sciences plc  
("Proteome Sciences" or the "Company")**

**Notice of Results**

Proteome Sciences will announce its interim results for the six months ended 30 June 2017 on 25 July 2017.

**For further information:**

**Proteome Sciences plc**

Dr Jeremy Haigh, Chief Executive Officer  
Dr Ian Pike, Chief Scientific Officer  
Geoff Ellis, Finance Director

Tel: +44 (0)20 7043 2116

**finnCap Limited (Nominated Adviser/Broker)**

Geoff Nash/James Thompson  
Tony Quirke (broking)

Tel: +44 (0)20 7220 0500

**IFC Advisory (Financial PR and IR)**

Tim Metcalfe/Graham Herring/Miles Nolan

Tel: +44 (0)20 3053 8671

**Notes for editors:**

Proteome Sciences is a leader in applied proteomics offering high sensitivity, proprietary technologies and workflows for mapping cell signalling pathways (SysQuant<sup>®</sup>, TMTcalibrator<sup>™</sup>) and for the discovery, validation and assay development of protein biomarkers. The company has its headquarters in London, UK, with laboratory facilities in Frankfurt, Germany from where the PS Biomarker Services<sup>™</sup> division provides outsourced proteomics services and proprietary biomarker assays to biopharmaceutical and diagnostics companies and to academia.

Proteome Sciences has patented several novel protein biomarkers for diagnostic and treatment applications in important areas of human therapeutics such as cancer, stroke and Alzheimer's disease, and these are available for license.

This announcement contains inside information for the purpose of Article 7 of EU Regulation 596/2014.